NTP TECHNICAL REPORT ON THE TOXICOLOGY AND CARCINOGENESIS STUDIES OF GINKGO BILOBA EXTRACT (CAS NO. 90045-36-6) IN F344/N RATS AND B6C3F1/N MICE (GAVAGE STUDIES)

NTP Technical Report on the Toxicology and Carcinogenesis Studies Series

Volumn TR-578, Issue , 2013, Pages 1-191

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85149244196     PISSN: 23788917     EISSN: 23788925     Source Type: Book Series    
DOI: None     Document Type: Review

References (171)

1. Abdel-Kader, R., Hauptmann, S., Keil, U., Scherping, I., Leuner, K., Eckert, A., and Müller, W.E. (2007). Stabilization of mitochondrial function by Ginkgo biloba extract (EGb 761). Pharmacol. Res. 56, 493-502.
2. Abebe, W., Herman, W., and Konzelman, J. (2011). Herbal supplement use among adult dental patients in a USA dental school clinic: Prevalence, patient demographics, and clinical implications. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 111, 320-325.
3. Aeschbacher, H.U., Meier, H., and Ruch, E. (1982). Nonmutagenicity in vivo of the food flavonol quercetin. Nutr. Cancer 4, 90-98.
4. Agha, A.M., El-Fattah, A.A., Al-Zuhair, H.H., and Al-Rikabi, A.C. (2001). Chemopreventive effect of Ginkgo biloba extract against benzo(a)pyrene-induced forestomach carcinogenesis in mice: Amelioration of doxorubicin cardiotoxicity. J. Exp. Clin. Cancer Res. 20, 39-50.
5. Agnolet, S., Jaroszewski, J.W., Verpoorte, R., and Staerk, D. (2010). (1)HNMR-based metabolomics combined with HPLC-PDA-MS-SPE-NMR for investigation of standardized Ginkgo biloba preparations. Metabolomics 6, 292-302.
6. Ahlemeyer, B., and Krieglstein, J. (2003). Neuroprotective effects of Ginkgo biloba extract. Cell. Mol. Life Sci. 60, 1779-1792.
7. Allen, D.G., Pearse, G., Haseman, J.K., and Maronpot, R.R. (2004). Prediction of rodent carcinogenesis: An evaluation of prechronic liver lesions as forecasters of liver tumors in NTP carcinogenicity studies. Toxicol. Pathol. 32, 393-401.
8. Al-Yahya, A.A., Al-Majed, A.A., Al-Bekairi, A.M., Al-Shabanah, O.A., and Qureshi, S. (2006). Studies on the reproductive, cytological and biochemical toxicity of Ginkgo biloba in Swiss albino mice. J. Ethnopharmacol. 107, 222-228.
9. Amacher, D.E., Paillet, S.C., Turner, G.N., Ray, V.A., and Salsburg, D.S. (1980). Point mutations at the thymidine kinase locus in L5178Y mouse lymphoma cells. II. Test validation and interpretation. Mutat. Res. 72, 447-474.
10. Anderson, D., Basaran, N., Dobrzyńska, M.M., Basaran, A.A., and Yu, T.W. (1997). Modulating effects of flavonoids on food mutagens in human blood and sperm samples in the comet assay. Teratog. Carcinog. Mutagen. 17, 45-58.
11. Arenz, A., Klein, M., Fiehe, K., Gross, J., Drewke, C., Hemscheidt, T., and Leistner, E. (1996). Occurrence of neurotoxic 4′-O-methylpyridoxine in Ginkgo biloba leaves, Ginkgo medications and Japanese Ginkgo food. Planta Med. 62, 548-551.
12. Ashby, J., and Tennant, R.W. (1991). Definitive relationships among chemical structure, carcinogenicity and mutagenicity for 301 chemicals tested by the U.S. NTP. Mutat. Res. 257, 229-306.
13. Bailer, A.J., and Portier, C.J. (1988). Effects of treatment-induced mortality and tumor-induced mortality on tests for carcinogenicity in small samples. Biometrics 44, 417-431.
14. Beer, S., Komatsubara, K., Bellovin, D.I., Kurobe, M., Sylvester, K., and Felsher, D.W. (2008). Hepatotoxininduced changes in the adult murine liver promote MYC-induced tumorigenesis. PloS One 3, e2493.
15. Bent, S., Goldberg, H., Padula, A., and Avins, A.L. (2005). Spontaneous bleeding associated with Ginkgo biloba: A case report and systematic review of the literature. J. Gen. Intern. Med. 20, 657-661.
16. Biber, A. (2003). Pharmacokinetics of Ginkgo biloba extracts. Pharmacopsychiatry 36 (Suppl. 1), S32-S37.
17. Biber, A, and Koch, E. (1999). Bioavailability of ginkgolides and bilobalide from extracts of Ginkgo biloba using GC/MS. Planta Med. 65, 192-193.
18. Bieler, G.S., and Williams, R.L. (1993). Ratio estimates, the delta method, and quantal response tests for increased carcinogenicity. Biometrics 49, 793-801.
19. Biggs, M.L., Sorkin, B.C., Nahin, R.L., Kuller, L.H., and Fitzpatrick A.L. (2010). Ginkgo biloba and risk of cancer: Secondary analysis of the Ginkgo Evaluation of Memory (GEM) Study. Pharmacoepidemiol. Drug Saf. 19, 694-698.
20. Bjeldanes L.F., and Chang G.W. (1977). Mutagenic activity of quercetin and related compounds. Science 197, 577-578.
21. Blumenthal, M., Ed. (1998). The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines. American Botanical Council, Austin, TX.
22. Boorman, G.A., Montgomery, C.A., Jr., Eustis, S.L., Wolfe, M.J., McConnell, E.E., and Hardisty, J.F. (1985). Quality assurance in pathology for rodent carcinogenicity studies. In Handbook of Carcinogen Testing (H.A. Milman and E.K. Weisburger, Eds.), pp. 345-357. Noyes Publications, Park Ridge, NJ.
23. Brinkley, T.E., Lovato, J.F., Arnold, A.M., Furberg, C.D., Kuller, L.H., Burke, G.L., Nahin, R.L., Lopez, O.L., Yasar, S., and Williamson, J.D. (2010). Effect of Ginkgo biloba on blood pressure and incidence of hypertension in elderly men and women. Am. J. Hypertens. 23, 528-533.
24. Brown J.P., and Dietrich P.S. (1979). Mutagenicity of plant flavonols in the Salmonella/mammalian microsome test: Activation of flavonol glycosides by mixed glycosidases from rat cecal bacteria and other sources. Mutat. Res. 66, 223-240.
25. Bucher, J.R., Shackelford, C.C., Haseman, J.K., Johnson, J.D., Kurtz, P.J., and Persing R.L. (1994). Carcinogenicity studies of oxazepam in mice. Fundam. Appl. Toxicol. 23, 280-297.
26. Caria, H., Chaveca, T., Laires, A., Rueff, J. (1995). Genotoxicity of quercetin in the micronucleus assay in mouse bone marrow erythrocytes, human lymphocytes, V79 cell line and identification of kinetochorecontaining (CREST staining) micronuclei in human lymphocytes. Mutat. Res. 343, 85-94.
27. Carver, J.H., Carrano, A.V., and MacGregor, J.T. (1983). Genetic effects of the flavonols quercetin, kaempferol, and galangin on Chinese hamster ovary cells in vitro. Mutat. Res. 113, 45-60.
28. Chandra, A., Li, Y.Q., Rana, J., Persons, K., Hyun, C., Shen, S., and Mulder, T. (2011). Qualitative categorization of supplement grade Ginkgo biloba leaf extracts for authenticity. J. Funct. Foods 3, 107-114.
29. Chiu, A.E., Lane, A.T., and Kimball, A.B. (2002). Diffuse morbilliform eruption after consumption of Ginkgo biloba supplement. J. Am. Acad. Dermatol. 46, 145-146.
30. Code of Federal Regulations (CFR) 21, Part 58.
31. Cox, D.R. (1972). Regression models and life-tables. J. R. Stat. Soc. B34, 187-220.
32. Crawford, B.D. (1985). Perspectives on the somatic mutation model of carcinogenesis. In Advances in Modern Environmental Toxicology. Mechanisms and Toxicity of Chemical Carcinogens and Mutagens (M.A. Mehlman, W.G. Flamm, and R.J. Lorentzen, Eds.), pp. 13-59. Princeton Scientific Publishing Co., Inc., Princeton, NJ.
33. Crebelli, R., Aquilina, G., Falcone, E., and Carere, A. (1987). Urinary and faecal mutagenicity in Sprague-Dawley rats dosed with the food mutagens quercetin and rutin. Food Chem. Toxicol. 25, 9-15.
34. Dardano, A., Ballardin, M., Ferdeghini, M., Lazzeri, E., Traino, C., Caraccio, N., Mariani, G., Barale, R., and Monzani, F. (2007). Anticlastogenic effect of Ginkgo biloba extract in Graves’ disease patients receiving radioiodine therapy. J. Clin. Endocrinol. Metab. 92, 4286-4289.
35. De Feudis, F.V. (1998). Ginkgo biloba extract (EGb 761): From Chemistry to the Clinic. Ullstein Medical, Wiesbaden.
36. De Feudis, F.V. (2003). A brief history of EGb 761 and its therapeutic uses. Pharmacopsychiatry 36 (Suppl. 1), S2-S7.
37. De Feudis, F.V., and Drieu, K. (2000). Ginkgo biloba extract (EGb 761) and CNS functions: Basic studies and clinical applications. Curr. Drug Targets 1, 25-58.
38. DeKosky, S.T., Williamson, J.D., Fitzpatrick, A.L., Kronmal, R.A., Ives, D.G., Saxton, J.A., Lopez, O.L., Burke, G., Carlson, M.C., Fried, L.P, Kuller, L.H., Robbins, J.A., Tracy R.P., Woolard N.F., Dunn, L., Snitz, B.E., Nahin, R.L., Furberg, C.D., and Ginkgo Evaluation of Memory (GEM) Study Investigators (2008). Ginkgo biloba for prevention of dementia: A randomized controlled trial. JAMA 300, 2253-2262, 2730.
39. Del Tredici, P. (1991). Ginkgos and people: A thousand years of interaction. Arnoldia 51, 2-15.
40. Diamond, B.J., Shiflett, S.C., Feiwel, N., Matheis, R.J., Noskin, O., Richards, J.A., and Schoenberger, N.E. (2000). Ginkgo biloba extract: Mechanisms and clinical indications. Arch. Phys. Med. Rehabil. 81, 668-678.
41. Dias, M.C., Rodrigues, M.A., Reimberg, M.C., and Barbisan, L.F. (2008). Protective effects of Ginkgo biloba against rat liver carcinogenesis. Chem. Biol. Interact. 173, 32-42.
42. Diwan, B.A., Henneman, J.R., and Rice, J.M. (1995). Further evidence for promoter-dependent development of hepatoblastoma in the mouse. Cancer Lett. 89, 29-35.
43. Dixon, W.J., and Massey, F.J., Jr. (1957). Introduction to Statistical Analysis, 2nd ed., pp. 276-278, 412. McGraw-Hill Book Company, Inc., New York.
44. Dunn, O.J. (1964). Multiple comparisons using rank sums. Technometrics 6, 241-252.
45. Dunnett, C.W. (1955). A multiple comparison procedure for comparing several treatments with a control. J. Am. Stat. Assoc. 50, 1096-1121.
46. Dunnick, J.K., and Hailey, J.R. (1992). Toxicity and carcinogenicity studies of quercetin, a natural component of foods. Fundam. Appl. Toxicol. 19, 423-431.
47. Duthie, S.J., Johnson, W., and Dobson, V.L. (1997). The effect of dietary flavonoids on DNA damage (strand breaks and oxidized pyrimdines) and growth in human cells. Mutat. Res. 390, 141-151.
48. Edenharder, R., and Grünhage, D. (2003). Free radical scavenging abilities of flavonoids as mechanism of protection against mutagenicity induced by tert-butyl hydroperoxide or cumene hydroperoxide in Salmonella typhimurium TA102. Mutat. Res. 540, 1-18.
49. Ehrlich, S.D. (2010). Ginkgo biloba. University of Maryland Medical Center.
50. Emerit, I., Arutyunyan, R., Oganesian, N., Levy, A., Cernjavsky, L., Sarkisian, T., Pogossian, A., and Asrian, K. (1995). Radiation-induced clastogenic factors: Anticlastogenic effect of Ginkgo biloba extract. Free Radic. Biol. Med. 18, 985-991.
51. Etheridge, A.S., Black, S.R., Patel, P.R., So, J., and Mathews, J.M. (2007). An in vitro evaluation of cytochrome P450 inhibition and P-glycoprotein interaction with goldenseal, Ginkgo biloba, grape seed, milk thistle, and ginseng extracts and their constituents. Planta Med. 73, 731-741.
52. Evans, G.O., Ed. (2009). General enzymology. In Animal Clinical Chemistry: A Practical Guide for Toxicologists and Biomedical Researchers, pp. 17-30. Taylor and Francis Group. Boca Raton, FL.
53. Fernandes, E.S., Pinto, R.M., de Paula Reis, J.E., de Oliveira Guerra, M., and Peters, V.M. (2010). Effects of Ginkgo biloba extract on the embryo-fetal development in Wistar rats. Birth Defects Res. B. Dev. Reprod. Toxicol. 89, 133-138.
54. Fransen, H.P., Pelgrom, S.M.G.J., Stewart-Knox, B., de Kaste, D., and Verhagen, H. (2010). Assessment of health claims, content, and safety of herbal supplements containing Ginkgo biloba. Food Nutr. Res. 54, 5221-DOI: 10.3402/fnr.v54i0.5221
55. Gart, J.J., Chu, K.C., and Tarone, R.E. (1979). Statistical issues in interpretation of chronic bioassay tests for carcinogenicity. JNCI 62, 957-974.
56. Gaspar, J., Rodrigues, A., Laires, A., Silva, F., Costa, S., Monteiro, M.J., Monteiro, C., and Rueff, J. (1994). On the mechanisms of genotoxicity and metabolism of quercetin. Mutagenesis 9, 445-449.
57. Gawron-Gzella, A., Marek, P., Chanaj, J., and Matławska, I. (2010). Comparative analysis of pharmaceuticals and dietary supplements containing extracts from the leaves of Ginkgo biloba L. Acta Pol. Pharm. 67, 335-343.
58. Girard, D.M., and Sager, D.B. (1987). The use of Markov chains to detect subtle variation in reproductive cycling. Biometrics 43, 225-234.
59. Granger, A.S. (2001). Ginkgo biloba precipitating epileptic seizures. Age Ageing 30, 523-525.
60. Gray, D.E., Messer, D., Porter, A., Ferguson, S., Harris, R.K., Clark, A.P., Algaier, J.W., Overstreet J.D., and Smith, C.S. (2005). Simultaneous quantification of terpenelactones and flavonol aglycones in hydrolyzed Ginkgo biloba extract by liquid chromatography with inline ultraviolet and evaporative light scattering detection. J. AOAC Int. 88, 1613-1620.
61. Gray, D.E., Messer, D., Porter, A., Hefner, B., Logan, D., Harris, R.K., Clark, A.P., Algaier, J.A., Overstreet, J.D., and Smith, C.S. (2007). Analysis of flavonol aglycones and terpenelactones in Ginkgo biloba extract: A comparison of high-performance thin-layer chromatography and column high-performance liquid chromatography. J. AOAC Int. 90, 1203-1209.
62. Guo, L., Mei, N., Liao, W., Chan, P.C., and Fu, P.P. (2010). Ginkgo biloba extract induces gene expression changes in xenobiotics metabolism and the Myc-centered network. OMICS 14, 75-90.
63. Hall, R.L. (2007). Clinical pathology of laboratory animals. In Animal Models in Toxicology, 2nd ed. (S.C. Gad, Ed.), pp. 787-830. Taylor and Francis Group, Boca Raton, FL.
64. Hard, G.C., Seely, J.C., Betz, L.J., and Havashi, S.M. (2007). Re-evaluation of the kidney tumors and renal histopathology occurring in a 2-year rat carcinogenicity bioassay of quercetin. Food Chem. Toxicol. 45, 600-608.
65. Hardigree, A.A., and Epler, J.L. (1978). Comparative mutagenesis of plant flavonoids in microbial systems. Mutat. Res. 58, 231-239.
66. Harwood, M., Danielewska-Nikiel, B., Borzelleca, J.F., Flamm, G.W., Williams, G.M., and Lines, T.C. (2007). A critical review of the data related to the safety of quercetin and lack of evidence of in vivo toxicity, including lack of genotoxic/carcinogenic properties. Food Chem. Toxicol. 45, 2179-2205.
67. Hasler, A. (2000). Chemical constituents of Ginkgo biloba. In Ginkgo Biloba (T.A. van Beek, Ed.), pp. 124-164. Harwood Academic Publishers, Amsterdam.
68. Hasler, A., Meier, B., and Sticher, O. (1992). Identification and determination of the flavonoids from Ginkgo-biloba by high-performance liquid-chromatography. J. Chromatogr. 605, 41-48.
69. Heads, J.A., Hawthorne, R.L., Lynagh, T., and Lynch, J.W. (2008). Structure-activity analysis of ginkgolide binding in the glycine receptor pore. J. Neurochem. 105, 1418-1427.
70. Heddle, J.A., Hite, M., Kirkhart, B., Mavournin, K., MacGregor, J.T., Newell, G.W., and Salamone, M.F. (1983). The induction of micronuclei as a measure of genotoxicity. A report of the U.S. Environmental Protection Agency Gene-Tox Program. Mutat. Res. 123, 61-118.
71. Hellum, B.H., Hu, Z., and Nilsen, O.G. (2007). The induction of CYP1A2, CYP2D6, and CYP3A4 by six trade herbal products in cultured human hepatocytes. Basic Clin. Pharmacol. Toxicol. 100, 23-30.
72. Hirono, I., Ueno, I., Hosaka, S., Takanashi, H., Matsushima, T., Sugimura, T., and Natori, S. (1981). Carcinogenicity examination of quercetin and rutin in ACI rats. Cancer Lett. 13, 15-21.
73. Huh, H., Staba, E.J., and Singh, J. (1992). Supercritical fluid chromatographic analysis of polyprenols in ginkgo-biloba-L. J. Chromatogr. 600, 364-369.
74. Ivic, L., Sands T.T., Fishkin, N., Nakanishi, K., Kriegstein, A.R., and Strømgaard, K. (2003). Terpene trilactones from Ginkgo biloba are antagonists of cortical glycine and GABA (A) receptors. J. Biol. Chem. 278, 49, 279-249, 285.
75. Izzo, A.A., and Ernst, E. (2001). Interactions between herbal medicines and prescribed drugs: A systematic review. Drugs 61, 2163-2175.
76. Jiang, X.Y., Qian, L.P., Zheng, X.J., Xia, Y.Y., Jiang, Y.B., and Sun da, Y. (2009). Interventional effect of Ginkgo biloba extract on the progression of gastric precancerous lesions in rats. J. Dig. Dis. 10, 293-299.
77. Jonckheere, A.R. (1954). A distribution-free k-sample test against ordered alternatives. Biometrika 41, 133-145.
78. Kajiyama, Y., Fuji, K., Takeuchi, H., and Manabe, Y. (2002). Ginkgo seed poisoning. Pediatrics 109, 325-327.
79. Kaplan, E.L., and Meier, P. (1958). Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53, 457-481.
80. Kellermann, A.J., and Kloft, C. (2011). Is there a risk of bleeding associated with standardized Ginkgo biloba extract therapy? Pharmacotherapy 31, 490-502.
81. Kennedy, J. (2005). Herb and supplement use in the US adult population. Clin. Ther. 27, 1847-1858.
82. Kleijnen, J., and Knipschild, P. (1992). Ginkgo biloba. Lancet 340, 1136-1139.
83. Kobayashi, D., Yoshimura, T., Johno, A., Sasaki, K., and Wada, K. (2011). Toxicity of 4′-O-methylpyridoxine-5′-glucoside in Ginkgo biloba seeds. Food Chem. 126, 1198-1202.
84. Kondratskaya, E.L., Lishko, P.V., Chatterjee, S.S., and Krishtal, O.A. (2002). BN52021, a platelet activating factor antagonist, is a selective blocker of glycine-gated chloride channel. Neurochem. Int. 40, 647-653.
85. Kressmann, S., Müller, W.E., and Blume, H.H. (2002). Pharmaceutical quality of different Ginkgo biloba brands. J. Pharm. Pharmacol. 54, 661-669.
86. Krizková, L., Chovanová, Z., Duracková, Z., and Krajcovic, J. (2008). Antimutagenic in vitro activity of plant polyphenols: Pycnogenol and Ginkgo biloba extract (EGb 761). Phytother. Res. 22, 384-388.
87. Kubiak, R., and Rudek, Z. (1990). SCEs and chromosome aberrations in mammalian cells in vitro treated with quercetin. Acta Biol. Hung. 41, 121-124.
88. Kuller, L.H., Ives, D.G., Fitzpatrick, A.L., Carlson, M.C., Mercado, C., Lopez, O.L., Burke, G.L., Furberg, C.D., DeKosky, S.T., and Ginkgo Evaluation of Memory Study Investigators (2010). Does Ginkgo biloba reduce the risk of cardiovascular events? Circ. Cardiovasc. Qual. Outcomes 3, 41-47.
89. Lepoittevin, J.P., Benezra, C., and Asakawa, Y. (1989). Allergic contact dermatitis to Ginkgo biloba L.: Relationship with urushiol. Arch. Dermatol. Res. 281, 227-230.
90. Li, C.L., and Wong, Y.Y. (1997). The bioavailability of ginkgolides in Ginkgo biloba extracts. Planta Med. 63, 563-565.
91. Li, X.F., Ma, M., Scherban, K., and Tam, Y.K. (2002). Liquid chromatography-electrospray mass spectrometric studies of ginkgolides and bilobalide using simultaneous monitoring of proton, ammonium and sodium adducts. Analyst 127, 641-646.
92. McConnell, E.E., Solleveld, H.A., Swenberg, J.A., and Boorman, G.A. (1986). Guidelines for combining neoplasms for evaluation of rodent carcinogenesis studies. JNCI 76, 283-289.
93. MacGregor, J.T., and Jurd, L. (1978). Mutagenicity of plant flavonoids: Structural requirements for mutagenic activity in Salmonella typhimurium. Mutat. Res. 54, 297-309.
94. MacGregor, J.T., Wehr, C.M., Henika, P.R., and Shelby, M.D. (1990). The in vivo erythrocyte micronucleus test: Measurement at steady state increases assay efficiency and permits integration with toxicity studies. Fundam. Appl. Toxicol. 14, 513-522.
95. McKenna, D.J., Jones, K., and Hughes, K. (2001). Efficacy, safety, and use of ginkgo biloba in clinical and preclinical applications. Altern. Ther. Health Med. 75, 70-86, 88-90.
96. Mahadevan, S., and Park, Y. (2008). Multifaceted therapeutic benefits of Ginkgo biloba L.: Chemistry, efficacy, safety, and uses. J. Food Sci. 73, R14-R19.
97. Mahady, G.B. (2002). Ginkgo biloba for the prevention and treatment of cardiovascular disease: A review of the literature. J. Cardiovasc. Nurs. 16, 21-32.
98. Maronpot, R.R., and Boorman, G.A. (1982). Interpretation of rodent hepatocellular proliferative alterations and hepatocellular tumors in chemical safety assessment. Toxicol. Pathol. 10, 71-80.
99. Maronpot, R.R., Yoshizawa, K., Nyska, A., Harada, T., Flake, G., Mueller, G., Singh, B., and Ward, J.M. (2010). Hepatic enzyme induction. Histopathology. Toxicol. Pathol. 38, 776-795.
100. Maruta, A., Enaka, K., and Umeda, M. (1979). Mutagenicity of quercetin and kaempferol on cultured mammalian cells. Gann 70, 273-276.
101. Mauri, P., Simonetti, P., Gardana, C., Minoggio, M., Morazzoni, P., Bombardelli, E., and Pietta, P. (2001). Liquid chromatography/atmospheric pressure chemical ionization mass spectrometry of terpene lactones in plasma of volunteers dosed with Ginkgo biloba L. extracts. Rapid Commun. Mass Spectrom. 15, 929-934.
102. Meltz, M.L., and MacGregor, J.T. (1981). Activity of the plant flavanol quercetin in the mouse lymphoma L5178Y TK+/− mutation, DNA single-strand break, and Balb/c 3T3 chemical transformation assays. Mutat. Res. 88, 317-324.
103. Miller, J.A., and Miller, E.C. (1977). Ultimate chemical carcinogens as reactive mutagenic electrophiles. In Origins of Human Cancer (H.H. Hiatt, J.D. Watson, and J.A. Winsten, Eds.), pp. 605-627. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.
104. Moreau, J.P., Eck, C.R., McCabe, J., and Skinner, S. (1986). Absorption, distribution and elimination of a labelled extract of Ginkgo biloba leaves in the rat [in French, English summary]. Presse Med. 15, 1458-1461.
105. Nagao, M., Morita, N., Yahagi, T., Shimizu, M., Kuroyanagi, M., Fukuoka, M., Yoshihira, K., Natori, S., Fujino, T., and Sugimura, T. (1981). Mutagenicities of 61 flavonoids and 11 related compounds. Environ. Mutagen. 3, 401-419.
106. National Toxicology Program (NTP) (1992). Toxicology and Carcinogenesis Studies of Quercetin (CAS No. 117-39-5) in F344/N Rats (Feed Studies). Technical Report Series No. 409. NIH Publication No. 92-3140. U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, Research Triangle Park, NC.
107. National Toxicology Program (NTP) (2000). Toxicology and Carcinogenesis Studies of Primidone (CAS No. 125-33-7) in F344/N Rats and B6C3F1 Mice (Feed Studies). Technical Report Series No. 476. NIH Publication No. 00-3966. U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, Research Triangle Park, NC.
108. Ndjoko, K., Wolfender, J., and Hostettmann, K. (2000). Determination of trace amounts of ginkgolic acids in Ginkgo biloba L. leaf extracts and phytopharmaceuticals by liquid chromatography-electrospray mass spectrometry. J. Chromatogr. B 744, 249-255.
109. Pennisi, R.S. (2006). Acute generalized exanthematous pustulosis induced by the herbal remedy Ginkgo biloba. Med. J. Aust. 184, 583-584.
110. Piegorsch, W.W., and Bailer, A.J. (1997). Statistics for Environmental Biology and Toxicology, Section 6.3.2. Chapman and Hall, London.
111. Pietta, P.G., Gardana, C., Mauri, P.L., Maffei-Fracino, R., and Carini, M. (1995). Identification of flavanoid metabolites after oral administration to rats of a Ginkgo biloba extract. J. Chromatogr. B Biomed. Appl. 673, 75-80.
112. Pietta, P.G., Gardana, C., and Mauri, P.L. (1997). Identification of Ginkgo biloba flavonol metabolites after oral administration to humans. J. Chromatogr. B Biomed. Sci. Appl. 693, 249-255.
113. Pinto, R.M., Fernandes, E.S., Reis, J.E., Peters, V.M., and Guerra Mde. O. (2007). Intra-uterine growth retardation after prenatal administration of Ginkgo biloba to rats. Reprod. Toxicol. 23, 480-485.
114. Portier, C.J., and Bailer, A.J. (1989). Testing for increased carcinogenicity using a survival-adjusted quantal response test. Fundam. Appl. Toxicol. 12, 731-737.
115. Portier, C.J., Hedges, J.C., and Hoel, D.G. (1986). Age-specific models of mortality and tumor onset for historical control animals in the National Toxicology Program’s carcinogenicity experiments. Cancer Res. 46, 4372-4378.
116. Rajaraman, G., Yang, G., Chen, J., and Chang, T.K. (2009). Modulation of CYP1B1 and CYP1A1 gene expression and activation of aryl hydrocarbon receptor by Ginkgo biloba extract in MCF-10A human mammary epithelial cells. Can. J. Physiol. Pharmacol. 87, 674-683.
117. ®. Planta Med. 76, 1683-1690.
118. Rao, G.N. (1996). New diet (NTP-2000) for rats in the National Toxicology Program toxicity and carcinogenicity studies. Fundam. Appl. Toxicol. 32, 102-108.
119. Rao, G.N. (1997). New nonpurified diet (NTP-2000) for rodents in the National Toxicology Program’s toxicology and carcinogenesis studies. J. Nutr. 127, 842s-846s.
120. Reed, C.J. (1993). Drug metabolism in the nasal cavity: Relevance to toxicology. Drug Metab. Rev. 25, 173-205.
121. Robertson, S.M., Davey, R.T., Voell, J., Formentini, E., Alfaro, R.M., and Penzak, S.R. (2008). Effect of Ginkgo biloba extract on lopinavir, midazolam and fexofenadine pharmacokinetics in healthy subjects. Curr. Med. Res. Opin. 24, 591-599.
122. Salvador, R.L. (1995). Herbal medicine - ginkgo. Can. Pharmacists J. 52, 39-41.
123. Schmid, W. (1975). The micronucleus test. Mutat. Res. 31, 9-15.
124. Sells, D.M., Brix, A.E., Nyska, A., Jokinen, M.P., Orzech, D.P., and Walker, N.J. (2007). Respiratory tract lesions in noninhalation studies. Toxicol. Pathol. 35, 170-177.
125. Shelby, M.D., and Witt, K.L. (1995). Comparison of results from mouse bone marrow chromosome aberration and micronucleus tests. Environ. Mol. Mutagen. 25, 302-313.
126. Shelby, M.D., Erexson, G.L., Hook, G.J., and Tice, R.R. (1993). Evaluation of a three-exposure mouse bone marrow micronucleus protocol: Results with 49 chemicals. Environ. Mol. Mutagen. 21, 160-179.
127. Shi, C., Liu, J., Wu, F., and Yew, D.T. (2010a). Ginkgo biloba extract in Alzheimer’s disease: From action mechanisms to medical practice. Int. J. Mol. Sci. 11, 107-123.
128. Shi, C., Fang, L., Yew, D.T., Yao, Z., and Xu, J. (2010b). Ginkgo biloba extract EGb761 protects against mitochondrial dysfunction in platelets and hippocampi in ovariectomized rats. Platelets 21, 53-59.
129. Shi, C., Xiao, S., Liu, J., Guo, K., Wu, F., Yew, D.T., and Xu, J. (2010c). Ginkgo biloba extract EGb761 protects against aging-associated mitochondrial dysfunction in platelets and hippocampi of SAMP8 mice. Platelets 21, 373-379.
130. Shinozuka, K., Umegaki, K., Kubota, Y., Tanaka, N., Mizuno, H., Yamauchi, J., Nakamura, K., and Kunitomo, M. (2002). Feeding of Ginkgo biloba extract (GBE) enhances gene expression of hepatic cytochrome P-450 and attenuates the hypotensive effect of nicardipine in rats. Life Sci. 70, 2783-2792.
131. Shirley, E. (1977). A non-parametric equivalent of Williams’ test for contrasting increasing dose levels of a treatment. Biometrics 33, 386-389.
132. Silva, I.D., Rodrigues, A.S., Gaspar, J., Maia, R., Laires, A., and Rueff, J. (1997). Involvement of rat cytochrome 1A1 in the biotransformation of kaempferol to quercetin: Relevance to the genotoxicity of kaempferol. Mutagenesis 12, 383-390.
133. Sloley, B.D., Tawfik, S.R., Scherban K.A., and Tam, Y.K. (2003). Quality control analyses for ginkgo extracts require analysis of intact flavonol glycosides. J. Food Drug Anal. 11, 102-107.
134. Smith, J.V., and Luo, Y. (2004). Studies on molecular mechanisms of Ginkgo biloba extract. Appl. Microbiol. Biotechnol. 64, 465-472.
135. Smith, P.F., Maclennan, K., and Darlington, C.L. (1996). The neuroprotective properties of the Ginkgo biloba leaf: A review of the possible relationship to platelet-activating factor (PAF). J. Ethnopharmacol. 50, 131-139.
136. Snitz, B.E., O’Meara, E.S., Carlson, M.C., Arnold, A.M., Ives, D.G., Rapp, S.R., Saxton, J., Lopez, O.L., Dunn, L.O., Sink, K.M., DeKosky, S.T., and Ginkgo Evaluation of Memory (GEM) Study Investigators (2009). Ginkgo biloba for preventing cognitive decline in older adults: A randomized trial. JAMA 302, 2663-2670.
137. Sowers, W.F., Weary, P.E., Collins, O.D., and Cawley, E.P. (1965). Ginkgo-tree dermatitis. Arch. Dermatol. 91, 452-456.
138. Sparreboom, A., Cox, M.C., Acharya, M.R., and Figg, W.D. (2004). Herbal remedies in the United States: Potential adverse interactions with anticancer agents. J. Clin. Oncol. 22, 2498-2503.
139. Stoewsand, G.S., Anderson, J.L., Boyd, J.N., Hrazdina, G., Babish, J.G., Walsh, K.M., and Losco, P. (1984). Quercetin: A mutagen, not a carcinogen, in Fischer rats. J. Toxicol. Environ. Health 14, 105-114.
140. Straus, D.S. (1981). Somatic mutation, cellular differentiation, and cancer causation. JNCI 67, 233-241.
141. Stromberg, P.C., and Vogtsberger, L.M. (1983). Pathology of the mononuclear cell leukemia of Fischer rats. I. Morphologic studies. Vet. Pathol. 20, 698-708.
142. Strømgaard, K., and Nakanishi, K. (2004). Chemistry and biology of terpene trilactones from Ginkgo biloba. Angew. Chem. Int. Ed. Engl. 43, 1640-1658.
143. Sugimura, T., Nagao, M., Matsushima, T., Yahagi, T., Seino, Y., Shirai, A., Sawamura, M., Natori, S., Yoshihira, K., Fukuola, M., and Kuroyanagi, M. (1977). Mutagenicity of flavone derivatives. Proc. Jpn. Acad. Ser. B 53, 194-197.
144. Tarone, R.E. (1975). Tests for trend in life table analysis. Biometrika 62, 679-682.
145. Tennant, R.W., Margolin, B.H., Shelby, M.D., Zeiger, E., Haseman, J.K., Spalding, J., Caspary, W., Resnick, M., Stasiewicz, S., Anderson, B., and Minor, R. (1987). Prediction of chemical carcinogenicity in rodents from in vitro genetic toxicity assays. Science 236, 933-941.
146. Tolman, K.G., and Rej, R. (1999). Liver function. In Tietz Textbook of Clinical Chemistry, 3rd ed. (C.A. Burtis and E.R. Ashwood, Eds.), pp. 1125-1177. W.B. Saunders Company, Philadelphia, PA.
147. Tomb, R.R., Foussereau, J., and Sell, Y. (1988). Mini-epidemic of contact dermatitis from ginkgo tree fruit (Ginkgo biloba L.). Contact Dermatitis 19, 281-283.
148. Turusov, V.S., Torii, M., Sills, R.C., Willson, G.A., Herbert, R.A., Hailey, J.R., Haseman, J.K., and Boorman, G.A. (2002). Hepatoblastomas in mice in the U.S. National Toxicology Program (NTP) studies. Toxicol. Pathol. 30, 580-591.
149. ®. Planta Med. 77, 259-264.
150. van Beek, T.A., and Montoro, P. (2009). Chemical analysis and quality control of Ginkgo biloba leaves, extracts, and phytopharmaceuticals. J. Chromatogr. A 1216, 2002-2032.
151. Van der Hoeven, J.C., Bruggeman, I.M., and Debets, F.M. (1984). Genotoxicity of quercetin in cultured mammalian cells. Mutat. Res. 136, 9-21.
152. Vilar, J.B., Leite, K.R., and Chen Chen L. (2009). Antimutagenicity protection of Ginkgo biloba extract (Egb 761) against mitomycin C and cyclophosphamide in mouse bone marrow. Genet. Mol. Res. 24, 328-333.
153. Walsh, K.M., and Courtney, C.L. (1998). Nasal toxicity of CI-959, a novel anti-inflammatory drug, in Wistar rats and Beagle dogs. Toxicol. Pathol. 26, 717-723.
154. Wang, C.G., Dai, Y., Li, D.L., and Ma, K.Y. (2010). Ginkgo biloba leaf extract action in scavenging free radicals and reducing mutagenicity and toxicity of cigarette smoke in vivo. J. Environ. Sci. Health A Tox. Hazard Subst. Environ. Eng. 45, 498-505.
155. Watson, D.G., and Oliveira, E.J. (1999). Solid-phase extraction and gas chromatography-mass spectrometry determination of kaempferol and quercetin in human urine after consumption of Ginkgo biloba tablets. J. Chromatogr. B Biomed. Sci. Appl. 723, 203-210.
156. Watson, W.A. (1982). The mutagenic activity of quercetin and kaempferol in Drosophila melanogaster. Mutat. Res. 103, 145-147.
157. Westendorf, J., and Regan, J. (2000). Induction of DNA strand-breaks in primary rat hepatocytes by ginkgolic acids. Pharmazie 55, 864-865.
158. Williams, D.A. (1971). A test for differences between treatment means when several dose levels are compared with a zero dose control. Biometrics 27, 103-117.
159. Williams, D.A. (1972). The comparison of several dose levels with a zero dose control. Biometrics 28, 519-531.
160. Williams, D.A. (1986). A note on Shirley’s nonparametric test for comparing several dose levels with a zero-dose control. Biometrics 42, 183-186.
161. Witt, K.L., Knapton, A., Wehr, C.M., Hook, G.J., Mirsalis, J., Shelby, M.D., and MacGregor, J.T. (2000). Micronucleated erythrocyte frequency in peripheral blood of B6C3F mice from short-term, prechronic, and chronic studies of the NTP Carcinogenesis Bioassay Program. Environ. Mol. Mutagen. 36, 163-194.
162. Woelkart, K., Feizlmayr, E., Dittrich, P., Beubler, E., Pinl, F., Suter, A., and Bauer, R. (2010). Pharmacokinetics of bilobalide, ginkgolide A and B after administration of three different Ginkgo biloba L. preparations in humans. Phytother. Res. 24, 445-450.
163. Woerdenbag, H.J., and De Smet, P.A.G.M. (2000). Adverse effects of and toxicity of Ginkgo extracts. In Ginkgo biloba (T.A. van Beek, Ed.), pp. 544-555. Harwood Academic Publishers, Amsterdam.
164. Woerdenbag, H.J., and van Beek, T.A. (1997). Ginkgo biloba. In Adverse Effects of Herbal Drugs (P.A.G.M. De Smet, K. Keller, R. Hänsel, and R.F. Chandler, Eds.), Vol. 3, pp. 51-66. Springer-Verlag, Berlin.
165. Xie, J., Ding, C., Ge, Q., Zhou, Z., and Zhi, X. (2008). Simultaneous determination of ginkgolides A, B, C and bilobalide in plasma by LC-MS/MS and its application to the pharmacokinetic study of Ginkgo biloba extract in rats. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 864, 87-94.
166. Ye, B., Aponte, M., Dai, Y., Li, L., Ho, M.C., Vitonis, A., Edwards, D., Huang, T.N., and Cramer, D.W. (2007). Ginkgo biloba and ovarian cancer prevention: Epidemiological and biological evidence. Cancer Lett. 251, 43-52.
167. Yeh, K.Y., Pu, H.F., Kaphle, K., Lin, S.F., Wu, L.S, Lin, J.H., and Tsai, Y.F. (2008). Ginkgo biloba extract enhances male copulatory behavior and reduces serum prolactin levels in rats. Horm. Behav. 53, 225-231.
168. Yoshida, M.A., Sasaki, M., Sugimura, K., and Kawachi, T. (1980). Cytogenetic effects of quercetin on cultured mammalian cells. Proc. Jpn. Acad. Ser. B 56, 443-447.
169. Zeiger, E., Haseman, J.K., Shelby, M.D., Margolin, B.H., and Tennant, R.W. (1990). Evaluation of four in vitro genetic toxicity tests for predicting rodent carcinogenicity: Confirmation of earlier results with 41 additional chemicals. Environ. Mol. Mutagen. 16 (Suppl. 18), 1-14.
170. Zeiger, E., Anderson, B., Haworth, S., Lawlor, T., and Mortelmans, K. (1992). Salmonella mutagenicity tests: V. Results from the testing of 311 chemicals. Environ. Mol. Mutagen. 19 (Suppl. 21), 2-141.
171. Zhou, Z., and Zheng, S. (2003). The missing link in Ginkgo evolution. Nature 423, 821-822.